Engineered PD-L1-targeted multifunctional proteins with self-prolonged circulation for enhanced tumor photothermal-immunotherapy.

ABSTRACT: In this study, a novel Immunoglobulin G (IgG) binding, Programmed Cell Death-Ligand 1 (PD-L1) targeting affibody, IgBD-Z_PD-L1, was constructed by genetically fusing the PD-L1-specific affibody ZM1 with the IgG-binding domain (IgBD). IgBD-Z_PD-L1 could simultaneously bind to IgG, PD-L1 receptor protein, and PD-L1-positive tumor cells. Furthermore, the fusion of IgBD significantly prolonged the in vivo circulation half-life of IgBD-Z_PD-L1 by binding to endogenous IgG, enhancing tumor accumulation and immunotherapeutic effects. Subsequently, anti-angiogenic/immunotherapeutic and dual-targeted combination immunotherapy strategies based on IgBD-Z_PD-L1 significantly improved tumor immunotherapy efficacy. Finally, IgBD-Z_PD-L1 was conjug

SUBMITTER: Zhao S 

PROVIDER: S-EPMC12702396 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature